Key points from article :
Unity Biotechnology's treatment for diabetic macular edema (DME), UBX1325, successfully achieved its primary endpoints in a 48-week phase 2 trial.
Single injection of UBX1325 significantly improved patients' vision throughout the trial compared to placebo, as measured by the early treatment of diabetic retinopathy study letter score.
UBX1325 also reduced the deterioration in retinal structure compared to placebo, and over half of the treated patients did not require anti-VEGF rescue treatment during the trial.
Unity Biotechnology declared UBX1325 to be safe and tolerable, with their positive data now propelling them towards a phase 2 comparison trial against Regeneron's Eylea, a prominent treatment for diabetic retinopathy in patients with DME.
Similar head-to-head trial targeting age-related macular degeneration expected to complete in August.
A corporate shift towards ophthalmology in 2022 led to half of the workforce being laid off.
